CervoMed Inc. Files 8-K with Regulatory Updates

TL;DR

CervoMed filed an 8-K on 4/23 for events on 4/22, covering Reg FD, other events, and financials.

AI Summary

CervoMed Inc. filed an 8-K on April 23, 2024, reporting on events as of April 22, 2024. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This 8-K filing provides important updates and disclosures from CervoMed Inc. to the SEC, which can impact investor understanding of the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• RestorGenex Corp (company) — Former company name
• Stratus Media Group, Inc (company) — Former company name
• 20240423 (date) — Filing date
• 20240422 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240422_8k.htm (8-K) — 30KB
• 0001437749-24-012761.txt ( ) — 160KB
• crvo-20240422.xsd (EX-101.SCH) — 3KB
• crvo-20240422_def.xml (EX-101.DEF) — 11KB
• crvo-20240422_lab.xml (EX-101.LAB) — 15KB
• crvo-20240422_pre.xml (EX-101.PRE) — 11KB
• crvo20240422_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Corporate Presentation Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company," "we" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act

01 Other Events

Item 8.01 Other Events As of April 22, 2024, 8,253,741 shares of the Company's common stock, par value $0.001 per share, are issued and outstanding.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 23, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR